FreePeptideCalc

Tesamorelin Dosage Calculator — EGRIFTA WR and SV Reconstitution

A GHRH analogue approved for HIV-associated lipodystrophy, and one of the few approved peptides that genuinely ships as a powder you reconstitute yourself.

Written by , who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Approved

FDA-approved

Approved in 2010, currently marketed as EGRIFTA WR and EGRIFTA SV. The label is explicit that the two are not substitutable — they have different vial strengths, different diluents and different reconstitution volumes. EGRIFTA WR is an 11.6 mg vial reconstituted with 1.3 mL of bacteriostatic water to a labelled 8 mg/mL, giving seven 1.28 mg daily doses of 0.16 mL each. EGRIFTA SV is a 2 mg vial reconstituted with 0.5 mL of sterile water and used immediately.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume
Syringe volume
Tesamorelin in the vial
Tesamorelin in the vial
EGRIFTA WR is 11.6 mg; EGRIFTA SV is 2 mg
Bacteriostatic water to add
Bacteriostatic water to add
mL
Dose per injection
Dose per injection
More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Draw to
14units(0.14 mL)
14 units01020304050Drag the plunger, or focus it and use the arrow keys
Draw to 14 units on a 50-unit U-100 syringe.
Concentration
8.92 mg/mL
Water added
1.3 mL
Doses in vial
9
How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

Drawing to the nearest printed mark delivers 1.25 mg rather than exactly 1.28 mg.
This syringe reads in 1-unit steps, so the closest drawable mark is 2.4% away from the target dose.

Key facts

Half-life
Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as
Egrifta, Egrifta WR, Egrifta SV

How good is the evidence?

An approved drug with a specific approved indication. Worth knowing that the WR label declares 8 mg/mL even though 11.6 mg in 1.3 mL is nominally 8.9 mg/mL — the labelled concentration accounts for overfill and is what governs, not your own division.

Tesamorelin dosage chart: EGRIFTA WR vs EGRIFTA SV

EGRIFTA WR is 1.28 mg once daily from a labelled 8 mg/mL solution: 0.16 mL, or 16 units on a U-100 syringe. EGRIFTA SV is 1.4 mg once daily from a 4 mg/mL solution: 0.35 mL, or 35 units. The two products are not substitutable, so this is a two-row comparison rather than one tesamorelin dose with two package sizes.

Neither label gives a separate weekly dose. Multiplying the daily label amounts by seven yields 8.96 mg per week for WR and 9.8 mg per week for SV, but those totals are arithmetic summaries, not once-weekly alternatives. Both labels specify daily administration and neither publishes a cycle, loading phase or bodybuilding schedule.

How long the reconstituted solution lasts

This is the rare case where a primary source answers the question directly, and the answer surprises people: reconstituted EGRIFTA WR is stored at room temperature, 20°C to 25°C (68°F to 77°F), and discarded 7 days after mixing. Not refrigerated. Not 28 days. Do not freeze it.

EGRIFTA SV is different again — it is reconstituted with sterile water and used immediately, with no in-use period at all, which is one of several reasons the label states the two products are not substitutable. Same molecule, two kits, two completely different answers to the same question.

If you have been given a general rule for how long a reconstituted peptide keeps, this pair is the cleanest demonstration that no such rule exists. Both figures are stability data for a specific formulation with a specific diluent, and neither transfers to the other product, let alone to a compounded vial with no stability testing behind it.

What the label reports as adverse reactions

The reactions reported above 5% are arthralgia, injection site erythema, injection site pruritus, pain in the extremities, peripheral oedema and myalgia. Grouped by mechanism, the label describes hypersensitivity reactions such as rash and urticaria, oedema-related reactions including arthralgia, extremity pain, peripheral oedema and carpal tunnel syndrome, hyperglycaemia, and injection site reactions.

Injection site reactions ran at 25% on tesamorelin against 14% on placebo over the first 26 weeks of the trials. That placebo figure is the useful half of the comparison, and it is the half that summaries usually drop: more than half the injection site reactions reported by treated patients also occurred in people injecting nothing.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

  1. FDA labelFDA / DailyMed
    EGRIFTA WR (tesamorelin) for injection — FDA prescribing information and Instructions for Use
  2. FDA labelFDA / DailyMed
    EGRIFTA SV (tesamorelin) for injection — FDA prescribing information
  3. FDA labelFDA / DailyMed
    Bacteriostatic Water for Injection, USP — FDA prescribing information (NDA 018802)